Starpharma Holdings Limited (SPL) AI Stock Analysis

• Market Cap: $36.80M
• Dividend Yield: N/A
• Average Volume (3M): 197.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.28
• Revenue Growth: -67.07%
• EPS Growth: -47.32%
• Country: AU
• Employees: 40
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.03
• Shares Outstanding: 418,224,800
• 10 Day Avg. Volume: 263,127
• 30 Day Avg. Volume: 197,782
• PEG Ratio: 0.06
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.44
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Starpharma Holdings Limited faces challenges with persistent losses despite revenue growth, reflected in a moderate financial performance score. Technical indicators suggest bearish sentiment, while valuation metrics highlight the speculative risk due to negative earnings. The lack of earnings call data and impactful corporate events means these factors do not influence the score.

Starpharma Holdings Limited Business Overview & Revenue Model

Company Description

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

How the Company Makes Money

Starpharma Holdings Limited generates revenue through multiple streams, primarily centered around its proprietary dendrimer technology. The company earns money by licensing its technology to pharmaceutical companies, providing them with innovative drug delivery solutions that enhance the efficacy and safety of existing drugs. Additionally, Starpharma earns revenue through the sale of its VivaGel products, which are marketed for sexual health and other uses. The company also engages in collaborative partnerships and research agreements with pharmaceutical and biotech firms, receiving milestone payments, royalties, and other financial benefits from these collaborations. These partnerships play a significant role in expanding the reach and application of Starpharma's technology in various therapeutic areas.

Starpharma Holdings Limited Financial Statement Overview

Summary

Starpharma Holdings Limited demonstrates growth potential with increasing revenues, yet persistent losses pose a challenge. The balance sheet is stable, supported by strong cash reserves. Cash flow issues highlight a need for operational improvements to achieve positive cash generation.

Income Statement

Starpharma Holdings Limited has shown significant revenue growth with a notable increase in total revenue from the previous year. However, the company continues to report negative net income and EBIT, which impacts its profitability margins. Gross profit margin is relatively high, indicating efficient cost management in production despite overall losses.

Balance Sheet

The company's balance sheet reflects moderate leverage with a manageable debt-to-equity ratio. The equity ratio indicates a solid capital structure, though a decline in stockholders' equity raises concerns. Cash reserves are strong, providing a buffer against liabilities.

Cash Flow

Operating cash flow remains negative, highlighting cash outflows from operations. While free cash flow has improved slightly, it remains negative, which could strain liquidity. The company has managed capital expenditures well, showing discipline in investment spending.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
4.16M	8.29M	2.94M	4.68M	1.80M	6.03M
	Gross Profit
-5.75M	7.66M	1.22M	1.91M	539.50K	4.23M
	EBIT
-26.06M	-15.16M	-24.67M	-23.89M	-28.67M	-21.43M
	EBITDA
-12.24M	-9.63M	-15.25M	-15.80M	-21.42M	-14.40M
	Net Income Common Stockholders
-12.52M	-8.16M	-15.64M	-16.15M	-19.73M	-14.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
20.28M	23.36M	35.18M	49.92M	60.50M	30.05M
	Total Assets
29.61M	36.81M	52.09M	66.17M	73.24M	39.08M
	Total Debt
2.48M	3.53M	8.27M	8.19M	1.17M	1.57M
	Net Debt
-17.80M	-19.83M	-26.91M	-41.73M	-59.33M	-28.48M
	Total Liabilities
6.44M	8.70M	17.27M	17.78M	10.94M	7.75M
	Stockholders Equity
23.17M	28.12M	34.81M	48.39M	62.30M	31.33M
Cash Flow		Free Cash Flow
-11.18M	-7.07M	-14.15M	-14.00M	-15.05M	-10.90M
	Operating Cash Flow
-11.07M	-6.98M	-13.53M	-13.16M	-14.81M	-10.78M
	Investing Cash Flow
-111.00K	-89.00K	-610.00K	-836.00K	-246.00K	-125.00K
	Financing Cash Flow
-654.00K	-4.75M	-695.00K	3.23M	46.30M	-584.00K

Starpharma Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:SPL, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.10, and below the 200-day MA of 0.10, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.79 is Neutral, neither overbought nor oversold. The STOCH value of 8.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:SPL.

Starpharma Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SHL	70 Outperform	AU$12.78B	23.35	6.86%	4.02%	10.15%	6.20%
Sector *	52 Neutral	$5.15B	3.02	-44.64%	2.83%	16.44%	-0.47%
SPL	42 Neutral	$36.80M	―	-43.63%	―	-67.07%	-47.32%

Starpharma Holdings Limited Corporate Events

Starpharma Advances Strategic Initiatives and Expands Market Presence

Starpharma Holdings Limited has reported significant progress in its strategic initiatives, including advancing partnerships and developing its DEP® SN38 clinical program based on FDA feedback. The company has launched new products and campaigns in various regions, reaffirmed its strategic priorities, and is focusing on enhancing its radiopharmaceutical program. Despite challenges in the biotech sector, Starpharma remains committed to leveraging its dendrimer technology for value generation through partnerships and innovative asset development.

Starpharma Announces Quotation of New Securities on ASX

Starpharma Holdings Limited has announced the quotation of 117,744 ordinary fully paid securities on the Australian Securities Exchange (ASX), following the exercise of options or conversion of convertible securities. This move is part of the company’s strategic efforts to enhance its financial flexibility and strengthen its market position, potentially impacting its stakeholders positively by increasing liquidity and investor interest.

Robmar Investments Acquires Substantial Stake in Starpharma Holdings

Robmar Investments Pty Limited has become a substantial holder in Starpharma Holdings Limited, a company that operates in the pharmaceutical industry. Starpharma is known for its innovative drug delivery systems and dendrimer technology, which are primarily focused on enhancing the effectiveness of pharmaceuticals. The acquisition of a substantial holding by Robmar Investments indicates a significant investment interest in Starpharma, potentially impacting the company’s market position and signaling confidence in its future prospects.

Starpharma Reports Revenue Growth and Regulatory Milestone for DEP® SN38

Starpharma Holdings Limited reported a 65% increase in adjusted revenue for the half-year ending December 2024, driven by research revenue from Petalion Therapeutics and increased product sales. The company also achieved a 29% reduction in operating loss, attributed to the completion of several DEP® clinical programs. A significant regulatory milestone was reached with the FDA’s positive feedback on the DEP® SN38 clinical pathway, enhancing its potential for treating platinum-resistant ovarian cancer. This progress, alongside ongoing partnerships and asset optimization, positions Starpharma for future growth and stakeholder engagement.